A high and increasing HPV prevalence in tonsillar cancers in Eastern Denmark, 2000-2010: The largest registry-based study to date

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2196-2203

  Garnaes, Emilie ^a   Kiss, Katalin ^a   Andersen, Luise ^b   Therkildsen, Marianne H ^a   Franzmann, Maria B ^c   Filtenborg Barnkob, Bettina ^d   Hoegdall, Estrid ^e   Krenk, Lene ^a   Josiassen, Michael ^a   Lajer, Christel B ^a   Specht, Lena ^a   Frederiksen, Kirsten ^f   Friis Hansen, Lennart ^a   Nielsen, Finn C ^a   Kjaer, Susanne K ^a   Norrild, Bodil ^g   Von Buchwald, Christian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d Department of Pathology Naestved Slagelse Hospital   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

HPV; Oropharyngeal cancer; P16; Tonsillar cancer

Indexed keywords

PROTEIN P16; VIRUS DNA;

ADULT; AGE; AMPLICON; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; DENMARK; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; PAPILLOMAVIRUS INFECTION; PATHOLOGIST; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TONSIL CANCER; TREND STUDY; WART VIRUS; GENETICS; HEAD AND NECK TUMOR; INCIDENCE; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; REGISTER; TONSIL TUMOR; VIROLOGY;

DENMARK; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REGISTRIES; TONSILLAR NEOPLASMS;

EID: 84923073169     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29254     Document Type: Article

References (50)

1. Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: Focus on human papillomavirus associated sites. Int J Cancer 2011;129: 733-41.
2. Lassen P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95: 371-80.
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. J Clin Oncol 2011;29: 4214-301.
4. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int J Cancer 2009;125: 362-6.
5. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994;186: 131-56.
6. Palefsky JM, Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am 2009;36: 187-200.
7. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 2009;10: 321-2.
8. Lajer CB, Garnaes E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-Associated cancers: Bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012;106: 1526-34.
9. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356: 1944-56.
10. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer-part 1: Epidemiology, presentation, and preservation. Clin Otolaryngol 2011;36: 65-8.
11. Chernock RD, El-Mofty SK, Thorstad WL, et al. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: Utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009;3: 186-94.
12. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS 2010;118: 510-9.
13. Hong AM, Dobbins TA, Lee CS, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010;103: 1510-7.
14. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2010;126: 1256-62.
15. de Martel C., Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012;13: 607-15.
16. Rodrigo JP, Heideman DA, Garcia-Pedrero JM, et al. Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer 2014; 134: 487-92.
17. Rietbergen MM, Leemans CR, Bloemena E, et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer 2013;132: 1565-71.
18. Schache AG, Liloglou T, Risk JM, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: Sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011;17: 6262-71.
19. Rotnaglova E, Tachezy R, Salakova M, et al. HPV involvement in tonsillar cancer: Prognostic significance and clinically relevant markers. Int J Cancer 2011;129: 101-10.
20. Melkane AE, Auperin A, Saulnier P, et al. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck 2014;36: 257-65.
21. St Guily JL, Jacquard AC, Pretet JL, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France-The EDiTH VI study. J Clin Virol 2011;51: 100-4.
22. Nichols AC, Palma DA, Dhaliwal SS, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol 2013;20: 212-9.
23. Avnstorp MB, Jensen RG, Garnaes E, et al. Human papillomavirus and oropharyngeal cancer in Greenland in 1994-2010. Int J Circumpolar Health 2013;72: 22386.
24. Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010;28: 3269-72.
25. Shin HR, Curado MP, Ferlay J, et al. Comparability and quality of data. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer Incidence in Five Continents Vol. IX. Lyon: International Agency for Research on Cancer, 2007: 57-94.
26. Gronhoj LC, Gyldenlove M, Jensen DH, et al. Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: A systematic review. Br J Cancer 2014; 110: 1587-94.
27. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121: 2465-72.
28. Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer 2014;134: 2366-72.
29. Pedersen C B. The Danish Civil Registration System. Scand J Public Health 2011;22-5.
30. Bjerregaard B, Larsen O B. The Danish Patholgy Register. Scand J Public Health 2011;72-4.
31. Lewis JS, Jr., Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: An entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010;34: 1088-96.
32. Lewis JS, Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012;6 Suppl 1: S75-S82.
33. Snijders PJ, van den Brule AJ, Schrijnemakers HF, et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990;71(Pt 1): 173-81.
34. Hannisdal K, Schjolberg A, De Angelis PM, et al. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol 2010;130: 293-9.
35. Marklund L, Nasman A, Ramqvist T, et al. Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med 2012;1: 82-8.
36. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005;11: 5694-9.
37. Kim SH, Koo BS, Kang S, et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 2007;120: 1418-25.
38. Lajer CB, Nielsen FC, Friis-Hansen L, et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: A prospective translational study. Br J Cancer 2011;104: 830-40.
39. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-Associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24: 736-47.
40. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours, 7th ed. New York: Wiley-Blackwell, 2009;18 p.
41. Lewis JS, Jr., Khan RA, Masand RP, et al. Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma-A prospective cohort and interobserver variability study. Histopathology 2012;60: 427-36.
42. Danish Health and Medicines Authority. The Danish Cancer Registry 2010. Copenhagen: Danish Health and Medicines Authority. 2011: 32p.
43. Danish Health and Medicines Authority. The Danish Cancer Registry 2000. Copenhagen: Danish Health and Medicines Authority. 2004: 17p.
44. Kjaer SK. Human papillomavirus (HPV) infection, cervical cancer and vaccination against HPV: A Nordic perspective. Acta Obstet Gynecol Scand 2007;86: 1286-9.
45. Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between Oral HPV16 infection and cytopathology: Evaluation of an oropharyngeal "Pap-Test Equivalent" in high-risk populations. Cancer Prev Res (Phila) 2011;4: 1378-84.
46. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-85.
47. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364: 401-11.
48. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 8: E68329.
49. Korostil IA, Ali H, Guy RJ, et al. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013;40: 833-5.
50. Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother 2014;10.